Why Gentian Diagnostics stock moves
Gentian Diagnostics rose slightly.
Written after the close on ·
Why today
16,413 news analyzed todayGentian Diagnostics rose slightly.
Gentian Diagnostics rose on a day the Oslo market fell sharply; the grant of share options was the cause.
Over the last five trading days, the stock rose slightly, moving against a sharply falling Oslo benchmark index.
Its move was an ordinary one, smaller than a normal day for this stock, on well below usual trading volume.
Heidi Vebø's appointment as R&D head, announced on Wednesday last week, starts on 18 January 2027.
Today's move of +1.30% was 1.0 times a normal day's 1.3%. Oslo Børs benchmark index moved −1.31% on the same day.
Gentian Diagnostics +1.30%
What analysts expect, and how often they have been right
Analysts’ estimates for Gentian Diagnostics.
Ratings
Price targets
Latest price 39.10 NOK
For the current fiscal year, expected earnings per share changed from 1.46 NOK three months ago to 1.90 NOK now. 2026 estimate: 1.90 NOK. 2027 estimate: 2.60 NOK. One analyst made these estimates.
Has the share price followed the business?
Price and earnings moved in the same direction: 1 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed +44% and earnings per share −70%.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.m NOK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capm NOK
Price and earnings moved in the same direction: 1 out of 3 years.Market cap (Now): 604 m NOKRevenue 2025: 176 m NOK
What the key figures say about Gentian Diagnostics
The figures connect what Gentian Diagnostics earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -1.53 NOK–2.87 NOK. Peers: Bactiguard Holding 0.22 SEK, Microbot Medical -$0.25, C-Rad 1.41 SEK. 2026 estimate: 1.90 NOK (1.90 NOK–1.90 NOK). 2027 estimate: 2.60 NOK (2.60 NOK–2.60 NOK).
What the company sold during the year.
2022–2025: 102 m NOK–176 m NOK. Peers: Bactiguard Holding 217 m SEK, Microbot Medical $0.3M, C-Rad 418 m SEK. 2026 estimate: 198 m NOK (198 m NOK–198 m NOK). 2027 estimate: 228 m NOK (228 m NOK–228 m NOK).
The percentage of revenue left after the costs of running the business.
2022–2025: −22.9%–14.4%. Peers: Bactiguard Holding 2.1%, Microbot Medical −5348.8%, C-Rad 13.1%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: −15.3%–23.3%. Peers: Bactiguard Holding 2.0%, Microbot Medical −32.9%, C-Rad 13.0%.
The price investors pay for each unit of annual earnings per share. Not shown for a loss.
2022–2025: 13.7–65.6. Peers: Bactiguard Holding 70.5, C-Rad 17.0. 2026 estimate: 20.6. 2027 estimate: 15.0.
What investors pay for each unit the company sells.
2022–2025: 3.98–6.22. Peers: Bactiguard Holding 2.56, Microbot Medical 215.47, C-Rad 1.89. 2026 estimate: 3.05. 2027 estimate: 2.65.
Money paid to shareholders per share, summed by calendar year.
2025–2025: 0.40 NOK–0.40 NOK.
The ordinary yearly dividend as a percentage of the share price.
2022–2025: 0.0%–0.7%. Peers: Bactiguard Holding 0.0%, Microbot Medical 0.0%, C-Rad 0.4%.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: -2.52–-2.34. Peers: Bactiguard Holding 2.59, C-Rad -1.81.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 3.12–4.36. Peers: Bactiguard Holding 1.73, Microbot Medical 1.08.
Market cap plus net debt, divided by operating earnings. This includes debt.
2022–2025: 25.6–29.9.
Cash left after investments, divided by the number of shares.
2022–2025: -1.86 NOK–2.06 NOK. Peers: Bactiguard Holding 0.79 SEK, Microbot Medical -$0.27, C-Rad 0.39 SEK.
The percentage of assets financed by shareholders’ equity.
2022–2025: 79.3%–84.5%.
The dividend explained
A dividend is money paid to shareholders. Gentian Diagnostics paid 0.60 NOK per share in the twelve months through November 6, 2026.
On the ex-dividend day, May 6, 2026, Gentian Diagnostics traded without the right to the 0.60 NOK dividend. The price went from 44.80 NOK to 39.50 NOK; including the dividend, the day's change was −10.5%. Entitlement passes from the company to shareholders on the ex-day; payment comes later.
2025: 0.40 NOK2026 so far: 0.60 NOK
Earnings report
On its last 16 report days Gentian Diagnostics usually moved about 2.5%. On a normal day it moves 1.3%.
−1.81% −6.90% −3.27% −7.89%
10,000 NOK in Gentian Diagnostics bought on December 14, 2016 is worth 15,400 NOK today, with dividends reinvested.
The same amount in OSEBX with dividends would have become 30,200 NOK.
What would 10,000 NOK in Gentian Diagnostics be worth today? →
What would 10,000 NOK in Gentian Diagnostics be worth today?
15,400 NOK
with dividends reinvested, bought on December 14, 2016. The same amount in OSEBX with dividends would have become 30,200 NOK.
The five biggest days of the journey
· −27.4% · the whole market rose 0.5% the same day
· +20.0% · the whole market rose 0.5% the same day
· +16.3% · the whole market rose 0.1% the same day
· +16.0% · the whole market rose 0.1% the same day
· +14.3% · the whole market fell 1.0% the same day
Earlier days
+2.09% Gentian Diagnostics rose slightly over the last five trading days, while the Oslo Børs benchmark index fell sharply, so it moved against the market. Read →
Gentian Diagnostics rose slightly over the last five trading days, while the Oslo Børs benchmark index fell sharply, so it moved against the market.
The move was ordinary in size, and trading was well below its usual level.
The company granted options to its chief executive, Matti Heinonen, its chief financial officer, Njaal Kind, and other key staff on Friday 6 November.
Options give staff the right to buy shares later at a set price, so this is a routine incentive step.
−3.26% Gentian Diagnostics fell sharply without a company-news explanation. Read →
Gentian Diagnostics fell sharply without a company-news explanation.
Over the same day, Oslo Børs fell sharply too, so the stock moved more than the market.
Trading volume was about six times its usual level, a sign of heavy activity.
Over the last five trading days, the stock was roughly unchanged while the market fell sharply, so it held up better than the index.
+3.66% Gentian Diagnostics rose sharply, against a falling market. Read →
Gentian Diagnostics rose sharply, against a falling market.
No company news from that session explains the move.
Over the last five trading days the stock was roughly unchanged, while the Oslo Børs benchmark index fell slightly, so it held up better than the market.
Its latest close sits well below its highest close of the past year, and above its lowest.
−0.78% Gentian Diagnostics barely moved. Read →
Gentian Diagnostics barely moved.
The stock fell slightly while the Oslo Børs benchmark index rose slightly, so it moved against the market.
No company news explains the session, so this was an ordinary day for the stock.
Over the last five trading days, the shares fell clearly, while the market rose sharply.
A key driver was likely the record third-quarter sales reported on October 20, which likely did not lift the shares as investors hoped.
+1.01% Gentian Diagnostics rose slightly with no company news explaining it. Read →
Gentian Diagnostics rose slightly with no company news explaining it.
Over the same day Oslo Børs rose clearly, so it moved in line with the market.
Over the last five trading days the stock rose clearly, against a roughly flat market, a big move for the company.
Earlier this week it reported record third-quarter sales, up 22 percent, which likely supported the rise.
The stock's latest close is well below its highest close of the past year, reached in mid January.
+4.71% Gentian Diagnostics rose clearly over the last five trading days, a big move for the stock. Read →
Gentian Diagnostics rose clearly over the last five trading days, a big move for the stock.
The Oslo market was roughly flat over the same days, so the rise was company-specific.
The main driver was the third-quarter report on Tuesday, which showed record sales of NOK 51.1 million, growth of 22% reported, and a higher EBITDA (earnings before interest, tax and depreciation) margin of 27%.
Stronger US sales, driven by its Cystatin C kidney test, and better production yields likely supported the gain.
+2.83% Gentian Diagnostics rose clearly, while the Oslo market fell sharply. Read →
Gentian Diagnostics rose clearly, while the Oslo market fell sharply.
The rise came against a falling market, so it looks company-specific rather than market-driven.
Over the last five trading days, the shares rose sharply, while the market was roughly flat.
That is a big move for this stock, roughly three times a normal five-day stretch.
The likely driver is the record third-quarter sales reported on Tuesday, with US sales up strongly.
−2.75% Gentian Diagnostics fell clearly without any company news explaining it. Read →
Gentian Diagnostics fell clearly without any company news explaining it.
It moved against a market that rose sharply over the same day, with trading about three times normal.
Over the last five trading days the shares were roughly unchanged, moving less than the market, which rose slightly.
The earlier news was strong: record third-quarter sales of NOK 51.1 million, up 22%, with better margins.
It came out the day before the last session, so it does not explain that day's drop on its own.
Learn more · Why do stocks go up and down?